Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers in Women With Obesity and Other Risk Factors for Breast Cancer
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 40
Maximum Age: 64
Healthy Volunteers: t
View:
• • BMI 30-45 kg/m2
‣ Female
⁃ Insurance approved or likely approved for tirzepatide clinical use \*
⁃ Additional risk factors for breast cancer other than obesity (any one or more) First or second degree with breast cancer Known high density on mammogram (heterogenous or extremely dense) Prior biopsy showing atypical hyperplasia or LCIS Prior treated DCIS Known carrier breast cancer predisposition gene mutation or known mutation in family member .
‣ 2- fold or higher estimated 10 year or lifetime risk compared to population by standard risk model (BCRAT, BCSC, IBIS
Locations
United States
Kansas
University of Kansas Medical Center
RECRUITING
Kansas City
University of Kansas Medical Center Breast Cancer Prevention Center
RECRUITING
Westwood
Contact Information
Primary
Bruce F Kimler, PhD
bkimler@kumc.edu
913-574-2796
Backup
Carol L Fabian, MD
cfabian@kumc.edu
913-588-7791
Time Frame
Start Date: 2024-09-14
Estimated Completion Date: 2025-12
Participants
Target number of participants: 20
Treatments
women using tirzepatide for weight loss
Women attending the University of Kansas Medical Center (KUMC) Weight Management Clinic
Related Therapeutic Areas
Sponsors
Leads: University of Kansas Medical Center